Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Myriad Genetics, Inc.
MYGN
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $566.7M
$5.99
▼ -0.17%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$3.53 - $8.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 6.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Extensive proprietary test portfolio with strong clinical validation and market recognition
- FDA-approved companion diagnostic tests integrated into cancer treatment pathways
- Strategic partnerships with Illumina and Intermountain Precision Genomics expanding capabilities
- Established relationships with oncologists, OB/GYNs, and mental health providers
- Decades of genetic testing expertise and data accumulation since 1991 founding
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Premium gross margins (70%)
Value
Extreme premium - high expectations embedded
Momentum
Hot
+26.3% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MYGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 5, 2026
Reported EPS of -$0.09 vs -$0.06 consensus (-50.0% surprise). Revenue of $200.4M vs $202.4M expected (-1.0%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-50.0%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+7%
-3%
+1%
-4%
-0%
+2%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$211.5M
$213.3M
$210.6M
$195.9M
$213.1M
$205.7M
$209.8M
$200.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
-17.0%
Wall Street consensus
3 analysts · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: TD Cowen · May 6, 2026
vs Industry
How MYGN stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related